Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033045 | 0.95 | CCR2 (0.44) | CCR2TACR1KCNH2CYP2D6TSHR | |
| SCHEMBL3037271 | 0.94 | CCR2 (0.45) | CCR2TACR1KCNH2CYP2D6TSHR | |
| SCHEMBL3034202 | 0.92 | CCR2 (0.45) | CCR2TACR1KCNH2CYP2D6TSHR | |
| SCHEMBL13222974 | 0.89 | CCR2 (0.47) | CCR2TACR1KCNH2CYP2D6TSHR | |
| SCHEMBL3036985 | 0.88 | CCR2 (0.44) | CCR2KCNH2CYP2D6TSHRGAA | |
| SCHEMBL3040986 | 0.87 | CCR2 (0.44) | CCR2 | |
| SCHEMBL3029674 | 0.87 | CCR2 (0.43) | CCR2TACR1KCNH2CYP2D6TSHR | |
| SCHEMBL3039479 | 0.86 | CCR2 (0.44) | CCR2KCNH2CYP2D6TSHRGAA | |
| SCHEMBL14221713 | 0.86 | CCR2 (0.41) | CCR2TACR1KCNH2CYP2D6TSHR | |
| SCHEMBL13244006 | 0.86 | L3MBTL1 (0.52) | CCR2KCNH2CYP2D6TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2008045564-A2 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | CCR2 1/4885TACR1 539/4885KCNH2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.